• Je něco špatně v tomto záznamu ?

Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study

C. Jackisch, SB. Kim, V. Semiglazov, B. Melichar, X. Pivot, C. Hillenbach, D. Stroyakovskiy, BL. Lum, R. Elliott, HA. Weber, G. Ismael,

. 2015 ; 26 (2) : 320-5. [pub] 20141117

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16010695

BACKGROUND: HannaH (NCT00950300) was a phase III, randomized, international, open-label study that compared pharmacokinetics (PK), efficacy, and safety of two different trastuzumab formulations [subcutaneous (s.c.) and intravenous (i.v.)] in HER2-positive, operable, locally advanced, or inflammatory breast cancer in the neoadjuvant/adjuvant setting. The co-primary end points, to show noninferiority of s.c. versus i.v. trastuzumab in terms of serum concentration (Ctrough) and pathologic complete response (pCR) were met; safety profiles were comparable at 12 months' median follow-up. Secondary end points included safety and tolerability, PK profile, immunogenicity, and event-free survival (EFS). We now report updated safety and efficacy data after a median follow-up of 20 months. PATIENTS AND METHODS: Patients (N = 596) were treated with eight cycles of neoadjuvant chemotherapy, administered concurrently with 3-weekly s.c. trastuzumab (fixed dose of 600 mg) or the standard weight-based i.v. method. Following surgery, patients continued trastuzumab treatment to complete 1 year of therapy. Updated analyses of PK, efficacy, safety, and immunogenicity data were carried out. RESULTS: s.c. trastuzumab was generally well tolerated and the incidence of adverse events (AEs), including grade 3 or 4 AEs, between treatment groups was comparable. A slightly higher incidence of serious AEs (SAEs), mainly due to infections, was reported with s.c. treatment {64 [21.5%; 95% confidence interval (CI) 17.0%-26.7%] versus 42 (14.1%; 95% CI 10.4%-18.6%) in the i.v. group}; however, the differences were small and often based on rare events, with no observable pattern across reported events. An early analysis of EFS showed rates of 95% in both groups 1 year postrandomization. Exploratory analyses did not reveal an association between toxicity and body weight or exposure. CONCLUSIONS: Overall, the safety profile of s.c. trastuzumab was consistent with the previously published data from HannaH and the known safety profile of i.v. trastuzumab. EFS rates were comparable between the i.v. and s.c. groups. CLINICAL TRIAL NUMBER: NCT00950300.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16010695
003      
CZ-PrNML
005      
20160412104347.0
007      
ta
008      
160408s2015 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/annonc/mdu524 $2 doi
024    7_
$a 10.1093/annonc/mdu524 $2 doi
035    __
$a (PubMed)25403587
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Jackisch, C $u Department of Obstetrics and Gynecology and Breast Cancer and Gynecology Cancer Center, Sana Klinikum Offenbach GmbH, Offenbach, Germany christian.jackisch@sana.de.
245    10
$a Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study / $c C. Jackisch, SB. Kim, V. Semiglazov, B. Melichar, X. Pivot, C. Hillenbach, D. Stroyakovskiy, BL. Lum, R. Elliott, HA. Weber, G. Ismael,
520    9_
$a BACKGROUND: HannaH (NCT00950300) was a phase III, randomized, international, open-label study that compared pharmacokinetics (PK), efficacy, and safety of two different trastuzumab formulations [subcutaneous (s.c.) and intravenous (i.v.)] in HER2-positive, operable, locally advanced, or inflammatory breast cancer in the neoadjuvant/adjuvant setting. The co-primary end points, to show noninferiority of s.c. versus i.v. trastuzumab in terms of serum concentration (Ctrough) and pathologic complete response (pCR) were met; safety profiles were comparable at 12 months' median follow-up. Secondary end points included safety and tolerability, PK profile, immunogenicity, and event-free survival (EFS). We now report updated safety and efficacy data after a median follow-up of 20 months. PATIENTS AND METHODS: Patients (N = 596) were treated with eight cycles of neoadjuvant chemotherapy, administered concurrently with 3-weekly s.c. trastuzumab (fixed dose of 600 mg) or the standard weight-based i.v. method. Following surgery, patients continued trastuzumab treatment to complete 1 year of therapy. Updated analyses of PK, efficacy, safety, and immunogenicity data were carried out. RESULTS: s.c. trastuzumab was generally well tolerated and the incidence of adverse events (AEs), including grade 3 or 4 AEs, between treatment groups was comparable. A slightly higher incidence of serious AEs (SAEs), mainly due to infections, was reported with s.c. treatment {64 [21.5%; 95% confidence interval (CI) 17.0%-26.7%] versus 42 (14.1%; 95% CI 10.4%-18.6%) in the i.v. group}; however, the differences were small and often based on rare events, with no observable pattern across reported events. An early analysis of EFS showed rates of 95% in both groups 1 year postrandomization. Exploratory analyses did not reveal an association between toxicity and body weight or exposure. CONCLUSIONS: Overall, the safety profile of s.c. trastuzumab was consistent with the previously published data from HannaH and the known safety profile of i.v. trastuzumab. EFS rates were comparable between the i.v. and s.c. groups. CLINICAL TRIAL NUMBER: NCT00950300.
650    _2
$a dospělí $7 D000328
650    _2
$a protinádorové látky $x aplikace a dávkování $x škodlivé účinky $x farmakokinetika $7 D000970
650    _2
$a nádory prsu $x farmakoterapie $x genetika $7 D001943
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a intravenózní infuze $7 D007262
650    _2
$a injekce subkutánní $7 D007279
650    _2
$a lidé středního věku $7 D008875
650    _2
$a receptor erbB-2 $x biosyntéza $x genetika $7 D018719
650    _2
$a trastuzumab $x aplikace a dávkování $x škodlivé účinky $7 D000068878
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kim, S-B $u Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
700    1_
$a Semiglazov, V $u Department of Surgery, NN Petrov Research Institute of Oncology, St Petersburg, Russia.
700    1_
$a Melichar, B $u Department of Oncology, Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic.
700    1_
$a Pivot, X $u Chemotherapy-Oncology, CHU Jean Minjoz, Besançon, France.
700    1_
$a Hillenbach, C $u Department of Biopharmaceuticals, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
700    1_
$a Stroyakovskiy, D $u Chemotherapeutic Department, City Clinical Oncology Hospital 62, Moscow, Russia.
700    1_
$a Lum, B L $u Clinical Pharmacology.
700    1_
$a Elliott, R $u BioAnalytical Sciences, Genentech, South San Francisco, USA.
700    1_
$a Weber, H A $u Department of Biopharmaceuticals, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
700    1_
$a Ismael, G $u Hospital Amaral Carvalho, Jaú, Brazil.
773    0_
$w MED00000432 $t Annals of oncology official journal of the European Society for Medical Oncology ESMO $x 1569-8041 $g Roč. 26, č. 2 (2015), s. 320-5
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25403587 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160408 $b ABA008
991    __
$a 20160412104430 $b ABA008
999    __
$a ok $b bmc $g 1114124 $s 935063
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 26 $c 2 $d 320-5 $e 20141117 $i 1569-8041 $m Annals of oncology $n Ann Oncol $x MED00000432
LZP    __
$a Pubmed-20160408

Najít záznam

Citační ukazatele

Možnosti archivace